Semaglutide is prescribed for: Weight loss in adult patients with an initial body mass index (BMI) of 30 kg/m2 or greater (obesity) Weight loss in adult patients with an initial body mass index (BMI) of 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (hypertension, type 2 diabetes mellitus, or dyslipidemia) Weight loss in pediatric patients aged 12 years and older with an initial BMI at the 95th percentile or greater for age and sex (obesity) Reducing the risk of major adverse cardiovascular events (non-fatal myocardial infarction, CV death, or non-fatal stroke) in adults with cardiovascular disease and either obesity or overweight Treating noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), formerly known as NASH, with moderate to advanced liver fibrosis (stages F2 to F3 fibrosis) in adults Patients taking semaglutide for any of these conditions, especially weight loss, are typically suggested to maintain a low-carb and low-fat diet

From superficial wounds to deep structural injuries, animal studies show consistent improvements in healing speed, tissue quality, and functional recovery
The peptide decreases infarct size, preserves cardiac function, and reduces arrhythmias in experimental myocardial infarction models
This is one reason MOTS-c is frequently discussed in longevity, performance, and metabolic-health communities
Fasting is defined as no consumption of food or beverage other than water for at least 12-14 hours before testing
When receiving high doses of vitamins and minerals intravenously, its important that treatment is given by our team of licensed professionals with careful planned doses for your needs